MRSN Mersana Therapeutics Inc.

4.97
+0.19  (+4%)
Previous Close 4.78
Open 4.83
Price To Book 1.91
Market Cap 237152779
Shares 47,716,857
Volume 137,481
Short Ratio
Av. Daily Volume 205,931

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be discontinued - noted January 4, 2019.
XMT1522
HER2 - breast cancer
Phase 1 data due at ASCO June 1, 2019, 8am CT.
XMT-1536
Ovarian Cancer, Non Small Cell Lung Cancer

Latest News

  1. Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
  2. Mersana Therapeutics, Inc. (MRSN) Q1 2019 Earnings Call Transcript
  3. Mersana Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Updates
  4. Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates
  5. Consider These 3 Falling Knives
  6. New Research: Key Drivers of Growth for Liberty Global, KKR Real Estate Finance Trust, AGCO, Model N, STAAR Surgical, and Mersana Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
  7. Mersana Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
  8. Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019
  9. What Should You Know About Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Earnings Trajectory?
  10. JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment
  11.  Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
  12. Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
  13. Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  14. Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business Updates
  15. The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
  16. Mersana Therapeutics Announces Pricing of Public Offering of Common Stock
  17. Mersana Therapeutics Announces Proposed Public Offering of Common Stock
  18. Mersana Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  19. Mersana CEO details path forward after breakup with Takeda
  20. Are Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Interest Costs Too High?